コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 PCPA alone significantly increased nose poke latency com
2 PCPA and TP+PCPA significantly decreased locomotor activ
3 PCPA significantly and substantially depleted 5-HT and 5
4 abels into the inactivator, [2,3-(13)C(2)]-1-PCPA, followed by analysis using on-line liquid chromato
5 d between the flavin cofactor of MAO N and 1-PCPA are similar to those reported for the irreversible
7 idence supports covalent attachment of the 1-PCPA inactivator to the cofactor as N(5)-3-oxo-3-phenylp
8 eversible inactivation product formed with 1-PCPA and mammalian mitochondrial monoamine oxidase B.
10 files of LSD1 activity and inactivation by 2-PCPA as a function of pH are consistent with a mechanism
12 ating that trans-2-phenylcyclopropylamine (2-PCPA, tranylcypromine, Parnate) was the most potent with
15 etic parameters of the inhibition of LSD1 by PCPA and determined the crystal structure of LSD1-CoREST
16 otonin depleting drug p-chlorophenylalanine (PCPA) or with the serotonin reuptake inhibitor fluoxetin
17 of 5-HT stores using p-chlorophenylalanine (PCPA), a 5-HT-synthesis inhibitor, abolished luminal fac
18 epleting 5-HT with para-chlorophenylalanine (PCPA) mimicked seizure-induced hypoventilation, partiall
19 tional experiments suggest cotranscriptional PCPA counteracted by U1 association with nascent transcr
20 also reveals that the phenyl ring of the FAD-PCPA adduct in LSD1 does not form extensive interactions
22 roup of mice pretreated with AMPT 100 mg/kg, PCPA 100 mg/kg or PRAZ 1 mg/kg, the effect of D1 was att
27 stnatal day 26 with parachlorophenylalanine (PCPA 100 mg/kg, every other day); controls received sali
28 y pretreatment with parachlorophenylalanine (PCPA), completely prevented the anticonvulsant action of
30 e in the presence of p-chloro-phenylalanine (PCPA), a tryptophan hydroxylase inhibitor, the serotonin
31 tidepressant trans-2-phenylcyclopropylamine (PCPA; tranylcypromine; Parnate), are also capable of inh
32 cing premature cleavage and polyadenylation (PCPA) and loss of expression of long (>45 kb) genes, a s
33 termination by cleavage and polyadenylation (PCPA) at cryptic polyadenylation signals (PASs) in intro
34 emature 3' end cleavage and polyadenylation (PCPA) from cryptic polyadenylation signals (PASs) in int
37 o inhibit splicing, dose-dependently shifted PCPA downstream and elicited mRNA 3' UTR shortening and
51 P significantly increased aggression whereas PCPA did not, suggesting that in a high-threat context,
52 ss spectrometry analyses are consistent with PCPA forming a covalent adduct with FAD in LSD1 that is